TAKEDA PHARMA (TKD HM) stock market data APIs
€26.0347
-0.17(-0.7%)
as of July 1, 2025
Try our APIs with
free plan!
TAKEDA PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TKD.HM.
Prev. Close
26.0347
Open
25.8654
High
26.0347
Low
25.8654
52 wk Range
22.9456-27.7195
Market Cap
37 823 M
Dividends (Yield)
3.2068
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TAKEDA PHARMA data using free add-ons & libraries
Get TAKEDA PHARMA Fundamental Data
TAKEDA PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TAKEDA PHARMA News
New
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Prim...
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Ser...
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases. ADMA’s lead product, Asceniv, is a plasma-derived Intrav...
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
CINCINNATI, June 25, 2025 /PRNewswire/ -- Scientists from Cincinnati Children's and colleagues based in Japan report achieving a major step forward in organoid technology--producing liver tissue that...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
